contact us

Use the form on the right to contact us.

You can edit the text in this area, and change where the contact form on the right submits to, by entering edit mode using the modes on the bottom right.

         

123 Street Avenue, City Town, 99999

(123) 555-6789

email@address.com

 

You can set your address, phone number, email and site description in the settings tab.
Link to read me page with more information.

ardenHEADER.jpg

Arden's Day Blog

Arden's Day is a type I diabetes care giver blog written by author Scott Benner. Scott has been a stay-at-home dad since 2000, he is the author of the award winning parenting memoir, 'Life Is Short, Laundry Is Eternal'. Arden's Day is an honest and transparent look at life with diabetes - since 2007.

type I diabetes, parent of type I child, diabetes Blog, OmniPod, DexCom, insulin pump, CGM, continuous glucose monitor, Arden, Arden's Day, Scott Benner, JDRF, diabetes, juvenile diabetes, daddy blog, blog, stay at home parent, DOC, twitter, Facebook, @ardensday, 504 plan, Life Is Short, Laundry Is Eternal, Dexcom SHARE, 生命是短暂的,洗衣是永恒的, Shēngmìng shì duǎnzàn de, xǐyī shì yǒnghéng de

Filtering by Tag: type 1

On This day, January 11 1922: Insulin Was First Used to Treat Diabetes

Scott Benner

On Jan. 11, 1922 fourteen-year-old Leonard Thompson was injected with a pancreatic extract prepared by Dr. Frederick Banting, and medical student, Charles Best.

from TheStar.com:

Although his blood sugars went down a little, there was not a lot of change following Thompson’s initial injection, according to the University of Toronto’s heritage website.

But biochemist Bert Collip, who had been working with Banting and Best in a lab provided by the university’s head physiologist, Prof. J.J.R.. Macleod, developed a method to refine the extract and daily injections of this extract started Jan. 23. Improvement was immediate and remarkable. The boy’s blood sugar levels dropped to normal levels (Thompson would live another 13 years with daily injections of insulin, before dying of tuberculosis.)

It was not a cure but it was a monumental breakthrough in treatment for what had been an untreatable disease.

In March, 1922 a paper describing the case of Leonard Thompson, and six other patients the Banting and Best team treated with the refined extract, was published in the Canadian Medical Association Journal. It was the first official announcement of an extract developed to alleviate the symptoms of diabetes.

A message of hope to sufferers from diabetes goes out authentically today from the medical research laboratories of the University of Toronto. The modesty of medical men and scientific investigators of the genuine brand attempts to minimize the results obtained. The harm of exaggeration and the injustice to both parents and research men in awakening false and premature hopes before the extracts can possibly be manufactured cannot be over-emphasized. But the fact remains that one of the most important discoveries in modern medical research has been made at the university here. It is not a cure for diabetes, its authors state. Within six months, however, their discovery will be used on a large scale, they hope, to prolong life quite considerably at least. There will be no secrecy, as from the beginning. The medical profession will know all the facts.
— The Toronto Daily Star - March 22, 1922 Edition

The Toronto Daily Star broke the news a day before other outlets. The March 22, 1922 bold all-capital headline ran eight columns on the front page: “Toronto doctors on track of diabetes cure.” A subhead stated: “Discovery made at University of Toronto will be means of prolonging life considerably — F.G. Banting and C.H. Best pushed experiments all last summer.”

The Star referred to the Alliston-born Banting — who had won the Military Cross in 1916 for bravery in World War I — as being “strangely slow in speech” and “unassuming” but he also had “the reputation of coming across with the punch at the critical moment.”

click to enlarge

Two months later, on May 22, 1922, Prof. Macleod delivered a paper on the U of T team’s findings to the American Association of Medical Physicists in Washington, D.C. and got a standing ovation. Macleod used the term “insulin” to describe the extract. According to the Canadian Encyclopedia, “in the eyes of most of the world,” this was considered the announcement of insulin.

The next year, on Oct. 26, 1923, the first Nobel prize awarded to Canadians was given to Banting and Macleod.

But the reaction of Banting and Macleod to the prize revealed a little of the testy relationship that had existed in the background between the two men.

According to an account on the website scienceheroes.com (similar to other published reports) Banting was furious that he was sharing the award with Macleod, not Best, and at first swore he “wouldn’t accept the award.” But friends persuaded him that it wouldn’t be smart to refuse the first Nobel for a Canadian (he remains the youngest Nobel Laureate in Physiology/Medicine). Instead, Banting announced he would split his share of the $40,000 monetary prize with Best.

read the story in it’s entirety at TheStar.com


Omnipod + Fiasp is cleared in Europe

Scott Benner

press release

Omnipod® Insulin Management System Now Available for Use in Europe with Fiasp® Fast-Acting Insulin

LONDON--(BUSINESS WIRE)--Oct. 2, 2018-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that Novo Nordisk’s Fiasp® (Fast-Acting Insulin Aspart) has been tested and found safe for use in Insulet’s Omnipod System in Europe. Fiasp® is a new-generation, ultra fast-acting insulin developed by Novo Nordisk that enters the bloodstream two times faster, compared to NovoRapid®, so it more closely matches a healthy body’s insulin response to a meal, thereby improving glycemic control. Insulet will showcase its Omnipod System during the European Association for the Study of Diabetes (EASD) annual meeting at the Messe Berlin Exhibition Halls in Berlin, Germany taking place 1st October to 5thOctober 2018.

This is the first European conference presence for Insulet since the Company assumed direct operations of its Omnipod System product line in Europe. At its booth (#3.P05), the Company will highlight the history of its innovation, from the current Omnipod System to its Omnipod Horizon™ Automated Glucose Control System currently in development. Insulet will also feature the Pod Challenge – an opportunity for attendees to wear a sample Pod to experience the freedom it allows patients.

“Our European team is thrilled for this opportunity to engage with leading regional healthcare practitioners and advocacy groups to showcase the unique benefits of our Omnipod System,” said DJ Cass, General Manager, Insulet Europe. “The addition of Fiasp for use with the Omnipod System provides another option for both patients and prescribers to support their diabetes management needs. EASD is an important venue for direct contact with the diabetes community across Europe so they can see firsthand how our innovative product will help make diabetes a smaller part of their patients’ lives.”

“It is encouraging to see that Fiasp keeps expanding its reach, potentially benefiting more people in need of it via the Insulet Omnipod System,” said Stephen Gough, Global Chief Medical Officer of Novo Nordisk. “With its ultra-fast acting profile, Fiasp has brought a new option for adults living with diabetes who require insulin to manage their post-meal spikes, and I am confident that they will find in Fiasp and the Omnipod System good allies to best manage their diabetes.”

Learn more about Omnipod today


My Father-Son Relationship interview with the BBC

Scott Benner

I was contacted recently by BBC World Services and asked to be part of a report they were doing about the relationships between fathers and sons. I want to thank reporter Nastaran Tavakoli-Far for using some of what I shared in her piece. It was incredibly interesting to listen while not knowing how much, if any, of what I shared would be used. The report is about 25 minutes long and features a number of fathers from all walks of life. Enjoy!

You can subscribe to the show here or listen online here… they cover a mired of topics.


Molly Fichtner named Head Coach at the University of Louisiana

Scott Benner

Congratulations to former Alabama catcher (and former Juicebox Podcast guest) Molly Fichtner on being named the Head Coach of the softball program at the University of Louisiana!

from SunBeltSports.org

Molly has an incredible passion for the game and is a tremendous leader. I look forward to seeing her impact and elevate the ULM softball program and having her in Louisiana.
— Jennie Finch, Olympic Gold Medalist

Molly Fichtner, who has seen success at the highest levels of the game, has been named ULM's seventh head softball coach, as announced by interim athletics director Scott McDonald on Friday, Sept. 21. The Houston, Texas, native has spent the last year as an assistant coach at East Carolina University. The appointment is pending approval by the University of Louisiana system's Board of Supervisors.
 
"Molly is highly-respected within the coaching community and her academic achievements garnered as a student-athlete have transferred over into her coaching career, leading her to great heights, and thankfully ULM," ULM Interim Athletics Director Scott McDonald said. "She has an outstanding reputation for player development and proven success in promoting the importance of academics with student-athletes. We are elated to have Molly join us at ULM, and we are thrilled about the impact she's going to have on the softball program and the community."
 
Fichtner makes the transition to ULM from Greenville where she was an assistant coach for the ECU softball program. Before her time with the Pirates, Fichtner spent two seasons in the same role at Dartmouth College.
 
After her honor-filled collegiate career, Fichtner remained at Alabama as a volunteer coach while pursuing her master's degree. After finishing her master's degree in 2015, she played one season in the National Fastpitch (NPF) league with the Dallas Charge.

You can read the rest of the article here.

Watch Molly’s press conference and listen to her appearance on the Juicebox Podcast.


Rule change for T1Ds and operating commercial motor vehicles

Scott Benner

Federal motor carrier safety administration (FMCSA), DOT rule change…

FMCSA revises its regulations to permit individuals with a stable insulin regimen and properly controlled insulin-treated diabetes mellitus to be qualified to operate commercial motor vehicles (CMVs) in interstate commerce!

from the American Diabetes Association:

The American Diabetes Association (ADA) applauds the U.S. Department of Transportation, Federal Motor Carrier Safety Administration (FMCSA) for its new rule permitting individuals with insulin-treated diabetes to be certified to operate commercial motor vehicles in interstate commerce. The new rule, published in the Federal Register yesterday, is the culmination of more than two decades of advocacy by the ADA to change the rules that govern commercial drivers with diabetes.

Since the 1990s, when Congress and FMCSA began studying the feasibility of licensing people who use insulin through waiver and exemption programs, ADA has been pushing for a medically-appropriate system to individually assess people with diabetes. Recognizing the discrimination that results when people are deemed unsafe simply because of how they treat their diabetes, ADA insisted on better, more fair rules. ADA celebrates the achievement of that goal today with FMCSA’s final rule.

FMCSA rules apply to most people who operate commercial motor vehicles – trucks, buses, construction vehicles, delivery vehicles, airport shuttles, etc. – in interstate commerce. In addition, many employers adopted the rule for their own use in evaluating workers, even if those workers were not directly subject to the rule itself. As a result, a rule that categorically excludes people who use insulin means people with diabetes are kept out of many jobs they are otherwise qualified to perform. The old rule contained a blanket exclusion against insulin use regardless of how well a person managed his or her diabetes. In 2003, FMCSA began granting exemptions to individuals who could satisfy safety criteria and wait out a long and cumbersome application process. The application process involved a period of many months during which the individual could not drive a commercial vehicle, often resulting in loss of income.

The new rule allows individuals on a stable insulin regimen to operate commercial vehicles without needing to obtain an exemption from the government. It provides for an appropriate assessment of diabetes by the individual’s treating clinician, followed by examination and certification from a certified medical examiner. “This rule eliminates a longstanding barrier that prevented people with diabetes from fully realizing their potential in the workforce,” said Katie Hathaway, JD, Vice President of Legal Advocacy for the American Diabetes Association. “I’m proud of ADA’s commitment to this issue and to leading the fight for what’s right for people with diabetes. We are so pleased to celebrate this victory alongside those affected by the outdated rule.”

Read the rest of the ADA’s statement here